Skip to main content
Livermore
Livermore
ZHEN

Mesoblast Ltd

MESO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001345099

No open-market purchases or sales by Mesoblast Ltd insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $53.3M in total; no superinvestor holds it.

Other share classesMEOBF

Q1 2022 vs. Q4 2021

How the institutions holding Mesoblast Ltd changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of MESO: Q4 2021 compared with Q1 2022
MeasureQ4 2021Of which not filed for Q1 2022Q1 2022Change
Holders42137−4
Shares3.32M773.17M−149.6K (−4.5%)
Value$16.2M$0$13.1M−$3.13M (−19.3%)

1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (4)

Institutions that held Mesoblast Ltd at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to MESO in Q1 2022
InstitutionSharesValue% of portfolio
Tobias Financial Advisors, Inc.20,000$84.0K0.03%
Susquehanna International Group, LLP18,778$79.0K0.00%
Summit X, LLC14,809$60.0K0.01%
Investors Research Corp1$00.00%

Sold out (8)

Institutions that held Mesoblast Ltd at the end of Q4 2021 and filed for Q1 2022 without it.

Institutions that sold out of MESO in Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
Goldman Sachs Group Inc55,042$264.0K
Citadel Advisors LLC41,598$200.0K
Sio Capital Management, LLC26,660$128.0K
Jane Street Group, LLC24,950$128.0K
Simplex Trading, LLC17,887$85.0K
JustInvest LLC10,956$53.0K
Tower Research Capital LLC (TRC)2,803$13.0K
Eaton Vance Management100$0

Not filed for Q1 2022 yet (1)

Institutions that held Mesoblast Ltd at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding MESO in Q4 2021 that haven't filed for Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
Bell Investment Advisors, Inc77$0